Neogenomics

Neogenomics Cash Ratio

Cash Ratio of Neogenomics (NEO) as of Nov 19, 2026.

Cash Ratio

-

Last updated:

Cash Ratio of Neogenomics is 2026 - . Cash Ratio of Neogenomics was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

On Eulerpool you can find the complete historical development of Cash Ratio Neogenomics since 2006 – with annual values, charts, and detailed analysis.

The Cash Ratio is the most conservative liquidity metric, comparing only cash and equivalents to current liabilities.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Ratio's Neogenomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neogenomics

All Key Metrics — Neogenomics